DxTherapeutics provides an end‑to‑end discovery platform for targeted protein degradation, combining AI, molecular dynamics, biophysical assays, and chemoproteomics to map induced‑proximity mechanisms and design novel degrader molecules. Their Auto/dx system leverages a proprietary Differentiated Therapeutic Knowledge Graph to automate target assessment, portfolio planning, and multi‑objective molecule design, dramatically reducing manual screening time and accelerating candidate selection for genetically defined disease drivers.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery for targeted protein degradation (TPD) is hindered by the vast, unmapped chemical space of E3-substrate interactions, lengthy literature and patent reviews, and the difficulty of designing molecules that reliably induce proximity for disease‑causing proteins.
Solution
DxTherapeutics offers an end‑to‑end discovery engine that integrates biophysical assays, chemoproteomics, molecular dynamics, artificial intelligence, and automation to map induced‑proximity mechanisms and design novel degrader molecules. Their Auto/dx platform builds a proprietary Differentiated Therapeutic Knowledge Graph to automate target assessment, portfolio planning, and multi‑objective molecule design, dramatically reducing manual screening time. The platform predicts the likelihood of successful degradation strategies and guides experimental validation, accelerating the progression from target identification to clinical candidate. By focusing on genetically defined disease drivers, DxTherapeutics aims to create disease‑modifying therapeutics for Mendelian disorders and oncology indications.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to develop targeted protein degraders for genetically defined diseases, as well as research collaborations focused on novel TPD therapeutics.
Features
- Proprietary Differentiated Therapeutic Knowledge Graph (DTKG) for systematic target and degradation strategy identification
- Auto/dx platform that automates literature, patent, and feasibility analysis to prioritize high‑unmet‑need targets
- AI‑driven multi‑objective molecular design coupled with physics‑based molecular dynamics simulations to predict degrader efficacy
- Integrated biophysical and chemoproteomic assays for rapid experimental validation of designed degraders
- End‑to‑end workflow from target discovery through translational studies, enabling accelerated candidate selection